**Supplementary Table 2. Characteristics and outcomes of the current and previously reported ICU populations with COVID-19**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Yang  (n=52) | Yu  (n=226) | Bhatraju (n=24) | Arentz  (n=21) | Wang  (n=36) | Graselli (n=1591) | Cummings  (n=257) | Barassa  (n=48) | Zangrillo  (n=73) | Mitra  (n=117) | SweCOVID (n=1563) |
| Age (years)  Mean (SD) or  Median (IQR) | 59·7 (13·3)  60-69: 33·3%  70-79: 15%  >80: 4% | 64 (57–60) | 64(18) | 70 (43–92) | 66 (57–78) | 63 (56–70)  0-50: 12·8%  51-60: 26·8%  61-70: 37·6%  71-80: 21·4%  >81: 1·4% | 62 (1–72)  20-49: 21.4%  20·2% 50-59  26·8% 60-69  20·2% 70-79  8·9% 80-89  2·3% >90 | 63 (51–75) | 61 (54–69) | 60 (60–79) | 61 (52–69) |
| Male | 67% | 61.5% | 63% | 52% | 61·1% | 82% | 67% | 56% | 86·3% | 67·5% | 74·7% |
| Symptom onset to ICU adm, days | 9·5 (7·0–12·5) | Not reported | 7 (4) to hospital admission | 3·5d to hospital admission | 10 (6–12) | Not reported | 5 (2–7) to hospital admission | 7 (5–12) | 9 (7–13) | 8 (4·5) to hospital admission | 10 (7–13) |
| Any comorbidity  -Diabetes  -Hypertension  -Cardiovascular  -Cardiac disease  -Lung disease  -CKD  -Obesity  -Immunosuppression | 40%  17%  ··  13.5%  10%  8%  ··  ··  ·· | 68.6%  20.8%  42.5%  ··  >9.7%  6.6%  3.5%  ··  0.4% | 87·5%  58%  ··  ··  ··  18%  21% | 85·7%  33·3%  ··  ··  43%  42%  47.6%  ··  14·3% | 72·2%  22·2%  58·3%  25%  ··  8.3%  5·6%  ··  ·· | 68%  17%  49%  21%  ··  4%  3%  ··  ·· | 82%  36%  63%  ··  19%  17%  14%  46%  ·· | ··  19%  44%  ··  10%  38%  ··  48%  6% | ··  13.6%  52·9%  ··  ··  9%  7·7%  29%  ·· | 73·5%  30·8%  46·2%  17.1%  ··  18.8%  12·8%  ··  ·· | 66.8%  24.6%  39%  ··  11·8%  14·8%  4·1%  18·1%  5·7% |
| APACHE score  (SD) or (IQR) | 17 (14–19) | Not reported | Not reported | Not reported | 17 (10–22) | Not reported | Not reported | 15 (5) | Not reported | 18 (10–28) | 53 (46–59)  \*SAPS III |
| Admission SOFA score (SD) or (IQR) | 4 (3–4) surv  6 (4–8)nonsurv | 4 (2–8) | Not reported | Not reported | 5(3–6) | Not reported | 11 (8–13) | 7(3) | Not reported | 6 (2–11) | 4 (0–7) |
| PaO2/FiO2 (mmHg)  Median (IQR) | 100 (66·6–126·7) survivors  62·5 (52–74·1) non-survivors | Not reported | 134 (108–171) on Day3 | 108 (58–247) nadir | 136 (103–234) | 160 (114–220) | 129 (80–203)  nadir | Not reported | 110 (80–185·5) Day 1 | 180 (148–216) after 24h of mechanical ventilation | 98 (75–140) on admission |
| Respiratory treatment  -invasive MV  -noninvasive MV  -HFNO  -prone positioning  -ECMO | 42%  56%  63·5%  11·5%  11·5% | 37.6%  8.8%  16.4%  9.7%  6.2% | 75%  0%  42%  28%  0% | 71%  19%  4·8%  50%  ·· | 47·2%  41·7%  11·1%  ··  11·1% | 88%  11%  ··  27%  1% | 79%  1%  5%  17%  3% | 94%  0%  6%  49%  2% | (Data for first 3d)  100%  ··  ··  76·4%  6·8 % | 63·2%  12.8%  36·8%  17·9%  2·6% | 81·2%  20·5%  30·9%  40·1%  <1% |
| Duration of IMV  (days) median (IQR) | Not reported |  | 10 (7–12) | Not reported | Not reported | Not reported | 18 (9–28) | Not reported | 10·1 (8–14·3) | 13·5 (8–22) | 12·3 (7·1–20) |
| Vasopressors/Inotropes | 35% |  | 71% | 67% | 36% | Not reported | 66% (n=257) | Not reported | 84·3% | 55·6% | 43·4% |
| CRRT/IHD | 17% | 10.6% | Not reported | Not reported | 5·6% | Not reported | 31% | Not reported | 21·9% | 13·7% | 18% |
| ARDS | 67% |  | 75% | 95·2% | 61·1% | Not reported | Not reported | 100% | 100% | Not reported | 80·3% |
| AKI  -KDIGO1  -KDIGO2  -KDIGO3 | 29% | 25.2%  10.2%  5.3%  9.7% | Not reported | 19·1% | 8·3% | Not reported | Not reported | Not reported | 75·3%  41·8%  27·3%  30·9% | Not reported | 46·6%  18·7%  10·4%  17·5% |
| Any antiviral treament  -Steroids  -HCq/Cq  -Remdesivir  -Lopinavir/Ritonavir  -IL-6 antagonists | 44%  58%  Not reported  Not reported  13·5%  Not reported | 51.8%  16.4%  Not reported  Not reported  5.3%  Not reported | 37·5%  0%  4·2%  29·2%  4·2%  0% | Not reported | 94·4%  72.2%  Not reported  Not reported  Not reported  Not reported | Not reported | 80·9%  26%  72%  9%  Not reported  17% | 94%  35%  94%  Not reported  94%  4% | 100%  100%  100%  Not reported  Not reported  Not reported | -  23·9%  0·9%  0%  NR  3·4% | 22·3%  1·7%  19·8%  0%  <0·5%  1·8% |
| ICU days (IQR) | Not reported  (23% not discharged) | Not reported | 9 (4–14)  (12.5% not discharged) | Not reported  (24% not discharged) | Not reported  (30.6% not discharged) | 9 (6–13)  (58% not discharged) | Not reported  (37% still in hospital, number in ICU not reported) | Not reported (47% not discharged) | 10·5 (8–15)  (45·4% not discharged) | 9 (5–21)  (10.3% not discharged) | 12 (5–21)  (1% not discharged) |
| Mortality | 61·5% | 38.5% | 50% | 67% | 17% | 27% | 39% | 36% at 28d  31% at 15d | 23·3% | 15·4% overall  17·1% with ICU outcome | 26·7% 30d mortality  23·2% ICU mortality |
| Length of follow-up | >28 days | 43 days | >14 (Range 14–28) | (Range 9–26) | (Range 6–34) | (Range 7–34) | Median 19 (9–30) | 15 days | Median 19 (15–27) | (Range 21–74) | 30 days |
| Deaths in persons >65 | 74·1% (>60yo) | 41·6% (>61yo)  (6% remaining in ICU/hospital) | 62%  (5·9% remaining in ICU/hospital) | Not reported | Not reported | 29·2% (>61yo)  (59% remaining in ICU) | Not reported | Not reported | Not reported | 21%  (25% remaining in ICU/hospital) | 43·9% |
| Deaths in persons >80 | 100% | 35·3% | Not reported | Not reported | Not reported | 54·5%  (38% remaining in ICU) | Approx. 64%  (interpreted from graph) | Not reported | Not reported | 31·3%  (12·5% remaining in ICU/hospital) | 60·4% |

APACHE= Acute Physiology and Chronic Health Evaluation; SOFA = Sequential Organ Failure Assessment; MV = mechanical ventilation; HFNO = high flow nasal oxygen; ECMO = extracorporeal membrane oxygenation; CRRT = continuous renal replacement therapy; IHD = intermittent hemodialysis; ARDS = acute respiratory distress syndrome; AKI = acute kidney injury; KDIGO = Kidney Disease Improving Global Outcomes; HCq = hydroxychloroquine; Cq = Chloroquine